More Missed Primary Endpoints in AD Trials

By bmartin on June 30, 2008 1:46 PM |

There are no optimistic forward-looking statements here.

Today, Myriad Genetics announced that its experimental agent tarenflurbil (Flurizan) failed to affect cognition or activities of daily living in early Alzheimer's disease, the primary endpoints of a large (N = 1600), 18-month, phase 3 trial. Tarenflurbil is an NSAID enantiomer of flurbiprofen. The company's CEO reported that, consequently, the development of the compound would be discontinued.

This news follows on the heels of the missed primary endpoints in a phase 2 trial of bapineuzumab in mild-to-moderate Alzheimer's disease, which were nevertheless spun as favorably as possible by developers Elan and Wyeth.

Categories:

Tags:

About this Entry

This page contains a single entry by bmartin published on June 30, 2008 1:46 PM.

Real Medical Drama Made Less Real by Singer-Songwriters was the previous entry in this blog.

WHO Recommends 2-Day Test for MDR-TB is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 4.01